Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Fuhong Hanlin (02696), which has increased over 24% in the month, with a current price of 70.85 HKD and a trading volume of 338 million HKD [1] Group 2 - On February 5, 2023, Eisai Co., Ltd. and Fuhong Hanlin announced an exclusive commercialization agreement for the anti-PD-1 antibody, Surufatinib, in the Japanese market, along with a joint exclusive development and production licensing agreement [1] - Eisai will pay Fuhong Hanlin an upfront payment of 75 million USD, with potential regulatory milestone payments up to 80.01 million USD, and sales milestone payments that could reach up to 233.3 million USD [1] - Fuhong Hanlin will also receive a double-digit percentage royalty based on product sales [1] Group 3 - On February 6, 2023, Dr. Zhu Jun, the Executive Director and CEO of Fuhong Hanlin, stated that the company had been strategically preparing for the Japanese market for three years and had formed a local team [1] - The decision to collaborate with Eisai instead of pursuing independent commercialization was influenced by the "very sincere" offer made by Eisai [1]
港股异动 | 复宏汉霖(02696)再涨超6% 月内涨超24% 公司将斯鲁利单抗日本权益授权给卫材